Stoke Therapeutics

Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
Fierce Biotech
Tue, 02/18/25 - 11:12 am
Biogen
R&D
Stoke Therapeutics
Dravet syndrome
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Pharma Voice
Tue, 11/26/24 - 09:45 am
Stoke Therapeutics
biotech
RNA
Dravet syndrome
Stoke's Dravet syndrome med released from partial clinical hold as company eyes phase 3 plans
Fierce Biotech
Wed, 08/7/24 - 11:31 am
Stoke Therapeutics
Dravet syndrome
STK-001
clinical trials
Stoke’s shares shoot up 90% as epilepsy drug slashes convulsive seizures
Fierce Biotech
Tue, 03/26/24 - 11:13 am
Stoke Therapeutics
antisense
seizures
Dravet syndrome
STK-001
Stoke faces new doubts in search for ‘Spinraza for epilepsy’
BioPharma Dive
Tue, 07/25/23 - 08:47 pm
Stoke Therapeutics
Dravet syndrome
epilepsy
STK-001
Stoke Looks to Pivotal Trial for Dravet Candidate
BioSpace
Mon, 11/14/22 - 07:01 pm
Stoke Therapeutics
Dravet syndrome
STK-001
clinical trials
Back to business for biotech flotations
EP Vantage
Wed, 07/3/19 - 09:48 am
IPOs
BridgeBio
Turning Point Therapeutics
Stoke Therapeutics
Prevail Therapeutics
Atreca
NGM Biopharmaceuticals
Akero Therapeutics
Milestone Pharmaceuticals
Morphic Therapeutics
Karuna
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D
Xconomy
Tue, 06/18/19 - 11:35 pm
Stoke Therapeutics
IPOs
Dravet syndrome
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Stoke Therapeutics Files for $86 Million IPO
CP Wire
Fri, 05/24/19 - 10:33 am
Stoke Therapeutics
Dravet syndrome
IPOs
Stoke Therapeutics Files for $86 Million IPO
Fri, 05/24/19 - 09:39 am
Stoke Therapeutics
Dravet syndrome
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Endpoints
Tue, 10/23/18 - 10:34 am
Stoke Therapeutics
Sarepta Therapeutics
What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll
Endpoints
Thu, 01/4/18 - 11:09 am
Sarepta Therapeutics
Ed Kaye
Stoke Therapeutics